PFA Pension Forsikringsaktieselskab Buys New Shares in AbbVie Inc. $ABBV

Key Points

• PFA Pension Forsikringsaktieselskab bought 1,053,486 shares of AbbVie in Q4 — a position valued at about $242 million, making AbbVie its 17th largest holding and comprising roughly 0.06% of the company's shares.
• AbbVie beat Q1 estimates (EPS $2.65 vs $2.59; revenue $15B vs $14.72B), raised its 2026 outlook as immunology drugs Skyrizi and Rinvoq help offset Humira declines, and analysts maintain a consensus rating of Moderate Buy with an average price target of $252.90.
• Despite the beat, sentiment is mixed: notable insider sales (including SVP David Ryan Purdue and EVP Perry C. Siatis) and concerns over Humira erosion, pipeline changes and valuation have kept some investors cautious.

PFA Pension Forsikringsaktieselskab bought a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,053,486 shares of the company's stock, valued at approximately $242,028,000. AbbVie makes up 0.7% of PFA Pension Forsikringsaktieselskab's holdings, making the stock its 17th biggest position. PFA Pension Forsikringsaktieselskab owned about 0.06% of AbbVie as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Chelsea Counsel Co. bought a new position in shares of AbbVie in the third quarter valued at $26,000. Westend Capital Management LLC bought a new position in AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the third quarter worth $31,000. WestEnd Advisors LLC boosted its position in AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock worth $32,000 after purchasing an additional 85 shares during the period. Finally, Caitlin John LLC bought a new position in AbbVie during the third quarter worth $33,000. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ABBV shares. Piper Sandler reduced their price objective on shares of AbbVie from $299.00 to $294.00 and set an "overweight" rating for the company in a research report on Thursday, April 23rd. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Guggenheim reaffirmed a "buy" rating and set a $249.00 price objective on shares of AbbVie in a research report on Friday. Morgan Stanley lifted their price objective on shares of AbbVie from $270.00 to $278.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, Evercore reduced their price objective on shares of AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a research report on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and an average price target of $252.90.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

Insider Transactions at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is owned by insiders.

AbbVie Stock Performance

Shares of AbbVie stock opened at $206.63 on Friday. The firm has a 50-day moving average of $214.55 and a 200-day moving average of $221.60. The stock has a market cap of $365.36 billion, a PE ratio of 101.79, a PEG ratio of 0.76 and a beta of 0.38. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts' expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. AbbVie's quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.46 earnings per share. Equities research analysts predict that AbbVie Inc. will post 14.21 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's payout ratio is 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.